INOVATYON/ ENGOT-ov5 study: Randomized phase III international study comparing trabectedin/pegylated liposomal doxorubicin (PLD) followed by platinum at progression vs carboplatin/PLD in patients with recurrent ovarian cancer progressing within 6-12 months after last platinum line

被引：13

作者：

Colombo, N. ^{[1
,2
]}

Gadducci, A. ^{[3
]}

Sehouli, J. ^{[4
]}

Rulli, E. ^{[5
]}

Maenpaa, J. ^{[6
,7
,8
,9
]}

Sessa, C. ^{[10
,11
]}

Montes, A. ^{[12
]}

Ottevanger, N. B. ^{[13
]}

Berger, R. ^{[14
,15
]}

Vergote, I. ^{[16
,17
]}

D'Incalci, M. ^{[5
,18
]}

Galaz, C. Churruca ^{[19
,20
]}

Chekerov, R. ^{[4
]}

Nyvang, G. B. ^{[21
,22
]}

Riniker, S. ^{[23
,24
]}

Herbertson, R. ^{[25
]}

Fossati, R. ^{[5
]}

Barretina-Ginesta, M. P. ^{[26
,27
]}

Deryal, M. ^{[28
,29
]}

Mirza, M. R. ^{[30
,31
]}

Biagioli, E. ^{[5
]}

Iglesias, M. ^{[32
,33
]}

Funari, G. ^{[5
]}

Romeo, M. ^{[34
,35
]}

Tasca, G. ^{[36
,37
]}

Pardo, B. ^{[38
]}

Tognon, G. ^{[39
,40
]}

Rubio-Perez, M. J. ^{[41
]}

DeCensi, A. ^{[42
]}

De Giorgi, U. ^{[43
]}

Zola, P. ^{[44
]}

Panici, P. Benedetti ^{[45
,46
]}

Aglietta, M. ^{[47
]}

Arcangeli, V. ^{[48
]}

Zamagni, C. ^{[49
]}

Bologna, A. ^{[50
]}

Westermann, A. ^{[51
]}

Heinzelmann-Schwarz, V. ^{[52
,53
]}

Tsibulak, I. ^{[14
,15
]}

Wimberger, P. ^{[54
,55
,56
,57
,58
]}

Poveda, A. ^{[59
,60
]}

机构：

[1] IRCCS, European Inst Oncol, Gynecol Canc Program, Milan, Italy

[2] Univ Milano Bicocca, Milan, Italy

[3] Univ Pisa, Div Obstet & Gynecol, Clin & Expt Med, Pisa, Italy

[4] Charite Berlin Univ Med, European Competence Ctr Ovarian Canc, North Eastern German Soc Gynecol Oncol NOGGO, Study Grp & Gynecol,Ctr Oncol Surg, Berlin, Germany

[5] Ist Ric Farmacol Mario Negri IRCCS, Milan, Italy

[6] Tampere Univ, Nord Soc Gynecol Oncol Clin Trial Unit NSGOCTU, Tampere, Finland

[7] Tampere Univ, Dept Obstet & Gynaecol, Tampere, Finland

[8] Tampere Univ, Tays Canc Ctr, Tampere, Finland

[9] Univ Hosp, Tampere, Finland

[10] Ist Oncol Svizzera Italiana, IOSI, Bellinzona, Switzerland

[11] Swiss Grp Clin Canc Res SAKK, Bellinzona, Switzerland

[12] Guys & St Thomas NHS Fdn Trust, London, England

[13] Radboud Univ Nijmegen, Med Ctr, Med Oncol, Nijmegen, Netherlands

[14] Med Univ Innsbruck, Dept Gynecol & Obstet, Innsbruck, Austria

[15] AGO, Innsbruck, Austria

[16] Univ Hosp Leuven, Leuven Canc Inst, Gynecol Oncol, Leuven, Belgium

[17] European Union, Belgian Gynaecol Oncol Grp BGOG, Leuven, Belgium

[18] Humanitas Univ, Dept Biomed Sci, Pieve Emanuele, Italy

[19] Hosp Donosti San Sebastian, De Donosti San, Spain

[20] Grp Espanol Canc Ovario GEICO, De Donosti San, Spain

[21] Odense Univ Hosp, Nord Soc Gynecol Oncol Clin Trial Unit NSGO CTU, Odense, Denmark

[22] Odense Univ Hosp, Dept Oncol, Odense, Denmark

[23] Kantonsspital St Gallen, Oncol, St Gallen, Switzerland

[24] Swiss Grp Clin Canc Res SAKK, St Gallen, Switzerland

[25] Brighton & Sussex Univ Hosp NHS Trust, Brighton, E Sussex, England

[26] Inst Catala Oncologia Girona, De Donosti San, Spain

[27] Girona & Grp Espanol Canc Ovario GEICO, De Donosti San, Spain

[28] North Eastern German Soc Gynecol Oncol NOGGO, Study Grp, Saarbrucken, Germany

[29] CaritasKlinikum St Theresia Saarbruecken, Saarbrucken, Germany

[30] Copenhagen Univ Hosp, Nord Soc Gynecol Oncol Clin Trial Unit NSGO CTU, Copenhagen, Denmark

[31] Copenhagen Univ Hosp, Dept Canc Treatment, Copenhagen, Denmark

[32] Hosp Son Llazter, Palma De Mallorca, Spain

[33] Grupo Espanol Canc Ovario GEICO, Palma De Mallorca, Spain

[34] Inst Catala Oncologia Badalona, De Donosti San, Spain

[35] Grp Espanol Canc Ovario GEICO, De Donosti San, Spain

[36] Inst Catala Oncol Hosp, Barcelona, Spain

[37] Grp Espanol Canc Ovario GEICO, Barcelona, Spain

[38] ASST Spedali Civili Univ Brescia, Obstetr & Gynaecol, Brescia, Italy

[39] Hosp Reina Sofia Cordoba, De Donosti San, Spain

[40] Grp Espanol Canc Ovario GEICO, De Donosti San, Spain

[41] EO Ospedali Galliera, SC Oncol Med, Genoa, Italy

[42] IRCCS Ist Romagnolo Studio Tumori IRST Dino Amado, Meldola, Italy

[43] AOU Citta Salute & Scienza OIRM S Anna, Turin, Italy

[44] AOU Policlin I Umberto Roma, Rome, Italy

[45] Univ Torino, Ist Candiolo, FPO IRCCS, Turin, Italy

[46] Univ Torino, Turin, Italy

[47] Ospedale Infermi, Rimini, Italy

[48] Univ Bologna, IRCCS Azienda Ospedaliero, Bologna, Italy

[49] IRCCS, Azienda Unita Sanit Locale Reggio Emilia, Reggio Emilia, Italy

[50] Amsterdam UMC, Amsterdam, Netherlands

来源：

BRITISH JOURNAL OF CANCER | 2023年 / 128卷 / 08期

关键词：

QUALITY-OF-LIFE; OPEN-LABEL; TRIAL; EFFICACY; MULTICENTER; SAFETY; SENSITIVITY; COMBINATION; EVALUATE; THERAPY;

D O I：

10.1038/s41416-022-02108-7

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

BACKGROUND: This trial investigated the hypothesis that the treatment with trabectedin/PLD (TP) to extend the platinum-free interval (TFIp) can improve overall survival (OS) in patients with recurrent ovarian cancer (OC). METHODS: Patients with OC (up to two previous platinum-based lines), with a TFIp of 6-12 months, were randomised to receive carboplatin/PLD (CP) or TP followed by platinum therapy at relapse. The primary endpoint was OS (HR: 0.75). RESULTS: The study enrolled 617 patients. The median TFIp was 8.3 months and 30.3% of patients had received two previous platinum lines. 74% and 73.9% of patients, respectively, received a subsequent therapy (ST) in the CP and TP arm; in the latter TP arm 87.2% of ST was platinum-based, as per protocol. The median OS was 21.4 for CP and 21.9 months for TP (HR 1.13; 95% CI: 0.94-1.35; p = 0.197). Grade 3-5 adverse reactions occurred in 37.1% of patients in the CP arm and 69.7% of patients in the TP arm, and the most frequent were neutropenia (22.8% CP, 39.5% TP), gastrointestinal (7.1% CP, 17.4% TP), hepatic (0.7% CP, 19.1% TP). CONCLUSIONS: This study did not meet the primary endpoint. CP combination remains the standard for patients with recurrent OC and a 6-12 months TFIp; TP is an effective treatment in patients suffering from persistent platinum toxicities.

引用

页码：1503 / 1513

页数：11

共 25 条

[11] Effect of BRCA1 and XPG mutations on treatment response to trabectedin and pegylated liposomal doxorubicin in patients with advanced ovarian cancer: exploratory analysis of the phase 3 OVA-301 study
Monk, B. J.
Ghatage, P.
Parekh, T.
Henitz, E.
Knoblauch, R.
Matos-Pita, A. S.
Nieto, A.
Park, Y. C.
Cheng, P. S.
Li, W.
Favis, R.
Ricci, D.
Poveda, A.
[J]. ANNALS OF ONCOLOGY, 2015, 26 (05) : 914 - 920
[12] A phase 3 randomized, open-label, multicenter trial for safety and efficacy of combined trabectedin and pegylated liposomal doxorubicin therapy for recurrent ovarian cancer
Monk, Bradley J.
Herzog, Thomas J.
Wang, George
Triantos, Spyros
Maul, Scott
Knoblauch, Roland
McGowan, Tracy
Shalaby, Waleed S. W.
Coleman, Robert L.
[J]. GYNECOLOGIC ONCOLOGY, 2020, 156 (03) : 535 - 544
[13] Trabectedin Plus Pegylated Liposomal Doxorubicin in Recurrent Ovarian Cancer
Monk, Bradley J.
Herzog, Thomas J.
Kaye, Stanley B.
Krasner, Carolyn N.
Vermorken, Jan B.
Muggia, Franco M.
Pujade-Lauraine, Eric
Lisyanskaya, Alla S.
Makhson, Anatoly N.
Rolski, Janusz
Gorbounova, Vera A.
Ghatage, Prafull
Bidzinski, Mariusz
Shen, Keng
Ngan, Hextan Yuen-Sheung
Vergote, Ignace B.
Nam, Joo-Hyun
Park, Youn Choi
Lebedinsky, Claudia A.
Poveda, Andres M.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (19) : 3107 - 3114
[14] A European, Observational, Prospective Trial of Trabectedin Plus Pegylated Liposomal Doxorubicin in Patients with Platinum-Sensitive Ovarian Cancer
Pignata, Sandro
Scambia, Giovanni
Villanucci, Alessandro
Naglieri, Emanuele
Ibarbia, Mikel Arruti
Brusa, Federica
Bourgeois, Hugues
Sorio, Roberto
Casado, Antonio
Reichert, Dietmar
Dopchie, Catherine
De Rivas, Beatriz
de Sande, Luis Miguel
[J]. ONCOLOGIST, 2021, 26 (04) : E658 - E668
[15] Randomized Controlled Trial Testing the Efficacy of Platinum-Free Interval Prolongation in Advanced Ovarian Cancer: The MITO-8, MaNGO, BGOG-Ov1, AGO-Ovar2.16, ENGOT-Ov1, GCIG Study
Pignata, Sandro
Scambia, Giovanni
Bologna, Alessandra
Signoriello, Simona
Vergote, Ignace B.
Wagner, Uwe
Lorusso, Domenica
Murgia, Viviana
Sorio, Roberto
Ferrandina, Gabriella
Sacco, Cosimo
Cormio, Gennaro
Breda, Enrico
Cinieri, Saverio
Natale, Donato
Mangili, Giorgia
Pisano, Carmela
Cecere, Sabrina Chiara
Di Napoli, Marilena
Salutari, Vanda
Raspagliesi, Francesco
Arenare, Laura
Bergamini, Alice
Bryce, Jane
Daniele, Gennaro
Piccirillo, Maria Carmela
Gallo, Ciro
Perrone, Francesco
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (29) : 3347 - +
[16] Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum-sensitive (platinum-free interval 6-12 months) subpopulation of OVA-301 phase III randomized trial
Poveda, A.
Vergote, I.
Tjulandin, S.
Kong, B.
Roy, M.
Chan, S.
Filipczyk-Cisarz, E.
Hagberg, H.
Kaye, S. B.
Colombo, N.
Lebedinsky, C.
Parekh, T.
Gomez, J.
Park, Y. C.
Alfaro, V.
Monk, B. J.
[J]. ANNALS OF ONCOLOGY, 2011, 22 (01) : 39 - 48
[17] Emerging treatment strategies in recurrent platinum-sensitive ovarian cancer: Focus on trabectedin
Poveda, Andres
Ray-Coquard, Isabelle
Romero, Ignacio
Antonio Lopez-Guerrero, Jose
Colombo, Nicoletta
[J]. CANCER TREATMENT REVIEWS, 2014, 40 (03) : 366 - 375
[18] Pegylated Liposomal Doxorubicin and Carboplatin Compared With Paclitaxel and Carboplatin for Patients With Platinum-Sensitive Ovarian Cancer in Late Relapse
Pujade-Lauraine, Eric
Wagner, Uwe
Aavall-Lundqvist, Elisabeth
Gebski, Val
Heywood, Mark
Vasey, Paul A.
Volgger, Birgit
Vergote, Ignace
Pignata, Sandro
Ferrero, Annamaria
Sehouli, Jalid
Lortholary, Alain
Kristensen, Gunnar
Jackisch, Christian
Joly, Florence
Brown, Chris
Le Fur, Nathalie
du Bois, Andreas
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (20) : 3323 - 3329
[19] Re: New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer)
Rustin, GJS
Quinn, M
Thigpen, T
du Bois, A
Pujade-Lauraine, E
Jakobsen, A
Eisenhauer, E
Sagae, S
Greven, K
Vergote, I
Cervantes, A
Vermorken, J
[J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2004, 96 (06): : 487 - 488
[20] Scambia G, 2022, J CLIN ONCOL, V40

← 1 2 3 →